Qiang Huang

Qiang Huang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YLYang Liu
Yang Liu
JLJie Lu
Jie Lu
ZZZhimeng Zhang
Zhimeng Zhang
LZLin Zhu
Lin Zhu
SDShicai Dong
Shicai Dong
QHQiang Huang
Qiang Huang
Glioblastoma multiforme (GBM) is the most prevalent form of malignant brain tumor. Amlexanox, a novel compound, has been shown to have anti-cancer potential. In this study, the anti-tumoral effects and the underlying mechanisms of amlexanox were investigated. Amlexanox significantly suppressed proliferation and invasion and induced apoptosis in glioblastoma cells. Furthermore, we found that amlexanox altered the protein expression of the Hippo pathway by downregulating IKBKE. Our data indicates that IKBKE directly targets LATS1/2 and induces degradation of LATS1/2, thereby inhibiting the activity of the Hippo pathway. In vivo results further confirmed the tumor inhibitory effect of amlexanox via the downregulation of IKBKE, and amlexanox induced no apparent toxicity. Collectively, our studies suggest that amlexanox is a promising therapeutic agent for the treatment of GBM.

6 January 2022 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
JLJiabo Li
Jiabo Li
XWXuya Wang
Xuya Wang
LCLulu Chen
Lulu Chen
JZJinhao Zhang
Jinhao Zhang
YZYiming Zhang
Yiming Zhang
XYXuejun YANG
Xuejun YANG
Glioblastoma is the most common primary intracranial malignant tumor in adults and has high morbidity and high mortality. TMEM158 has been reported to promote the progression of solid tumors. However, its potential role in glioma is still unclear. Here, we found that TMEM158 expression in human glioma cells in the tumor core was significantly higher than that in noncancerous cells at the tumor edge using bioinformatics analysis. Cancer cells in patients with primary GBMs harbored significantly higher expression of TMEM158 than those in patients with WHO grade II or III gliomas. Interestingly, regardless of tumor grading, human glioma samples that were IDH1-wild-type (IDH1-WT) exhibited higher expression of TMEM158 than those with IDH1-mutant (IDH1-Mut). We also illustrated that TMEM158 mRNA expression was correlated with poor overall survival in glioma patients. Furthermore, we demonstrated that silencing TMEM158 inhibited the proliferation of glioma cells and that TMEM158 overexpression promoted the migration and invasion of glioma cells by stimulating the EMT process. We found that the underlying mechanism involves STAT3 activation mediating TMEM158-driven glioma progression. In vivo results further confirmed the inhibitory effect of the TMEM158 downregulation on glioma growth. Collectively, these findings further our understanding of the oncogenic function of TMEM158 in gliomas, which represents a potential therapeutic target, especially for GBMs.

29 September 2021 in Cell Cycle
Verified
Journal Article
Closed access
XCXingjie Chen
Xingjie Chen
YLYalin Lu
Yalin Lu
HYHao Yu
Hao Yu
KDKangjie Du
Kangjie Du
YZYu Zhang
Yu Zhang
QHQiang Huang
Qiang Huang
MYBL2 has been demonstrated to be an oncogene in some cancers, but there is no pan-cancer analysis at the macro level. We used multiple online or offline bioinformatic tools to examine the effects of MYBL2 in human cancers. We first identified that MYBL2 was highly expressed and related to the stage and grade of most cancers. The results of survival analysis from two databases showed that high MYBL2 expression was positively correlated with a poor prognosis for most cancer patients. We observed a significant difference in the promoter methylation level of MYBL2 in cancers such as colon adenocarcinoma and liver hepatocellular carcinoma versus normal controls. We found that MYBL2 can affect the tumor immune microenvironment by influencing the immune infiltration level and expression level of CD4+ T cells, CD8+ T cells, cancer-associated fibroblasts (CAFs) and immune checkpoint-associated cells. Functional enrichment analysis of MYBL2 identified that MYBL2 can play a crucial role in cancers by regulating spliceosomes, DNA replication and the cell cycle. Moreover, we verified the function of MYBL2 in three cancer cells of glioma, breast cancers and liver cancers, and the results showed that MYBL2 can regulate the cell cycle and proliferation ability of cancers

22 January 2022 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
WXWei Xie
Wei Xie
QJQiwei Jiang
Qiwei Jiang
XWXueji Wu
Xueji Wu
LWLei Wang
Lei Wang
BGBing Gao
Bing Gao
JGJIANPING GUO
JIANPING GUO

10 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JLJie Lu
Jie Lu
YYYi Yang
Yi Yang
GGGaochao Guo
Gaochao Guo
YLYang Liu
Yang Liu
ZZZhimeng Zhang
Zhimeng Zhang
QHQiang Huang
Qiang Huang
IKBKE regulates cell proliferation and epithelial–mesenchymal transition of human malignant glioma via the Hippo pathway IKBKE regulates cell proliferation and epithelial–mesenchymal transition of human malignant glioma via the Hippo pathway

1 March 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YTYuan Tian
Yuan Tian
SHShaobo Hao
Shaobo Hao
MYMinhua Ye
Minhua Ye
AZAnling Zhang
Anling Zhang
YNYang Nan
Yang Nan
YZYue Zhong
Yue Zhong